A compact synthetic pathway rewires cancer signaling to therapeutic effector release
Author(s) -
H. Kay Chung,
Xinzhi Zou,
Bryce T. Bajar,
Veronica R. Brand,
Yunwen Huo,
Javier F. Alcudia,
James E. Ferrell,
Michael Z. Lin
Publication year - 2019
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.aat6982
Subject(s) - effector , cancer cell , crispr , erbb , biology , computational biology , cancer , oncogene , signal transduction , apoptosis , cancer research , microbiology and biotechnology , gene , genetics , cell cycle
Seeking and destroying cancer cells Rather than inhibiting aberrant signaling in cancer cells, what if that signal was put to work in detecting and destroying the cancer cells? Such an anticancer strategy could be based on the ErbB family of receptors that is activated in many cancers. Chunget al. developed a cell-killing circuit that is activated by excessive ErbB signaling and used a viral delivery system to add it to cells. The ErbB receptor proteins are tyrosine kinases that autophosphorylate. The authors designed a protease that would be recruited to such over-phosphorylated receptors. Once in place, the protease cleaves a protein anchored to the cell membrane, releasing it into the cytoplasm where it causes death of the transformed cells.Science , this issue p.eaat6982
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom